State-of-the-Art Care for Patients With NF1 Inoperable Plexiform Neurofibromas

Join us for this dynamic webinar on current and emerging therapeutic strategies for treating pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas! Hear how the experts leverage the latest data to manage both common and challenging cases, from using genetic alterations to guide treatment to leveraging novel targeted agents for optimal care.

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Welcome and Introductions
  • Pathophysiology and Current Management of NF1
  • A Targeted Therapy Approach to Improving Patient Outcomes in NF1
  • Panel Discussion: Barriers to Therapy, Future Directions, and Challenging Cases
  • Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Faculty
Scott R. Plotkin, MD, PhD

Faculty
Brian D. Weiss, MD

Goal Statement
The goal of this activity is to improve the knowledge and competence of pediatric medical oncologists and other healthcare professionals using novel-targeted therapies in the treatment of pediatric patients with neurofibromatosis type 1 plexiform neurofibromas.

Target Audience
This activity is intended for pediatric oncologists and other healthcare professionals who care for pediatric patients with neurofibromatosis type 1 who have inoperable plexiform neurofibromas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the characteristics of current and emerging therapeutic strategies in the treatment of pediatric patients with neurofibromatosis type 1 who have inoperable plexiform neurofibromas
  • Discuss the prognostic and potential predictive implications for genetic alterations to guide therapy decisions for patients with inoperable plexiform neurofibromas
  • Plan the use of novel targeted agents for patients with neurofibromatosis type 1 who have inoperable plexiform neurofibromas based on recent safety and efficacy data
  • Manage adverse events associated with systemic treatment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.